- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05446961
Clinical Study to Evaluate the Effect of Food Supplement in People Infected With Coronavirus
Pilot Phase II Randomized, Placebo-Controlled Clinical Trial for the Prevention and Progression of SARS-CoV-2 Infection of Subjects and Patients Using a Supplement Treatment With Carnipure Tartrate ( LCLT)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
After being informed about the study and potential risks, all patients given written informed consent will be divided em two cohorts according to inclusion criteria.One group with patients with diagnosed mild SARS-Cov-2 infection and another with healthy contacts of patients with diagnosed mild SARS-Cov-2.
Both groups will be randomized to receive either LCLT supplementation or placebo during 21 days. After this period primary endpoints of efficacy will be assessed.
Clinical follow up evaluations will be monitored (Cohort 1 and 2), and chest tomography will be monitored in cohort 2 as well. Subjects will be followed for safety through 8 weeks (cohort 1) and 6 weeks (cohort 2) after being included into the study.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Bahia
-
Salvador, Bahia, Brazil, 41650-010
- SENAI CIMATEC
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Cohort 1:
- males and females between 55 years and 85 years of age;
- history of close contact (cohabit) with a Family member or a person newly diagnosed with SARS-CoV-2 infection;
- negative RT-PCR COVID-19 test on the screening immediately after contact and prior to start treatment of the study.
Cohort 2:
- males and females between 18 years and 85 years of age;
- positive RT-PCR COVID-19 test and medical history and physical exam compatible with asymptomatic or mild COVID-19 pneumonia. Evaluation of clinical outcomes: oxygen requirements, hospitalization breathless and others;
Female subjects of childbearing potential must :
- have a negative serum pregnancy test at screening and a negative urine pregnancy test on the day of each study supplementation;
- no breast-feeding;
- agree to use one of the following methods of contraception from enrollment in study until 30 days after last supplementation (only if in sexual relationships with men): hormonal (e.g. oral, transdermal, intravaginal, implant, or injection); double barrier (i.e., condom, diaphragm, or cervical cap with spermicide); intrauterine device (IUD) or system (IUS); vasectomized partner (6 months minimum); or abstinence; bilateral tubal ligation (if no conception post-procedure); tubal occlusion; or bilateral salpingectomy. Women are considered non-child-bearing potential if they are post-menopausal (defined as at least 12 months spontaneous amenorrhea and confirmed with FSH > 40 mIU/ml) or have had documented hysterectomy and/or oophorectomy. system (IUS); vasectomized partner (6 months minimum); or abstinence; bilateral tubal ligation (if no conception post-procedure); tubal occlusion; or bilateral salpingectomy;
- Normal laboratory values of sodium, potassium, ALT, AST, total bilirubin, alcaline phosphatase, creatinine, fasting glucose, total WBC count, hemoglobina and platelet count;
- No medical history of alcohol or drug abuse
Exclusion Criteria:
- Hormonal replacement therapy;
- Severe COVID-19 pneumonia according to CDC criteria;
- Positive test for hepatitis B surface antigen, hepatitis C virus antibody, or human immunodeficiency virus types 1 or 2 antibodies;
- Participation in another experimental protocol and/or receipt of any investigational products within the past 3 months prior to Screening;
- Immunosuppressive cytotoxic therapies (e.g., chemotherapy drugs or radiation) in the past 6 months prior to Screening;
- Subjects unable to sign the inform consent to participate into the study;
- History of any other acute or uncontrolled chronic illness (including, hypertension, cardiovascular, pulmonary, neurological, hepatic, rheumatic, hematological, metabolic or renal disorders) that is not on medication regimen for at least the past 6 months;
- Medication or supplements that may interfere with the evaluation of the safety and tolerability of the study drug such as ACE Inhibitors, Angiotensin II Receptor Blockers (ARBs) (e.g. vitamin B3 and L-carnitine/acetyl-carnitine).
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Factorial Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: covid 19 LCLT supplement
LCLT is made out of 68% elemental L-carnitine and 32 % Tartric acid and therefore the EFSA (European Food Safety Authority) stated that it is safety up to at least 3 g.
Each 3 g of LCLT delivers 2 g of elemental L-carnitine L-carnitine and Tartric acid, 3g oral capsules daily use for 21 days
|
3 g orally capsules
Other Names:
|
Placebo Comparator: covid 19 placebo
The formulation will contain all salt ingredients v/v without LCLT (made out of 68% elemental L-carnitine and 32 % Tartric acid) and is replaced by Maltodextrin in the placebo capsules Placebo capsules daily for 21 days
|
orally capsules
|
Active Comparator: Healthy LCLT supplement
LCLT is made out of 68% elemental L-carnitine and 32 % Tartric acid and therefore the EFSA (European Food Safety Authority) stated that it is safety up to at least 3 g.
Each 3 g of LCLT delivers 2 g of elemental L-carnitine L-carnitine and Tartric acid, 3g oral capsules daily use for 21 days
|
3 g orally capsules
Other Names:
|
Placebo Comparator: Healthy Placebo
The formulation will contain all salt ingredients v/v without LCLT (made out of 68% elemental L-carnitine and 32 % Tartric acid) and is replaced by Maltodextrin in the placebo capsules Placebo capsules daily for 21 days
|
orally capsules
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number new SARS-CoV-2 cases at 21 days assessed by RT-PCR
Time Frame: 21 days
|
Number new SARS-CoV-2 cases at 21 days assessed by RT-PCR
|
21 days
|
Number of participants with severe COVID pneumonia measured by the presence of ground-glass opacity, consolidations, parenchymal bands, and crazy-paving pattern in chest tomography
Time Frame: 21 days
|
Number of participants with severe COVID pneumonia measured by the presence of ground-glass opacity, consolidations, parenchymal bands, and crazy-paving pattern in chest tomography
|
21 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Levels of C-Reactive Protein (CRP) from baseline to 7, 14 and 21 days
Time Frame: 1,7,14 and 21 days
|
Levels of C-Reactive Protein (CRP) from baseline to 7, 14 and 21 days
|
1,7,14 and 21 days
|
Total white blood count (1000 per mm³) from baseline to 7, 14 and 21 days
Time Frame: 1,7,14 and 21 days
|
Total white blood count (1000 per mm³) from baseline to 7, 14 and 21 days
|
1,7,14 and 21 days
|
Levels of plasma ACE1 and ACE2 receptors from baseline to 7, 14 and 21 days
Time Frame: 1, 7, 14 and 21 days
|
Levels of plasma ACE1 and ACE2 receptors from baseline to 7, 14 and 21 days
|
1, 7, 14 and 21 days
|
ACE1/ACE2 ratio from baseline to 7, 14 and 21 days days until the end of the study of each cohort
Time Frame: 1, 7, 14 and 21 days
|
ACE1/ACE2 ratio from baseline to 7, 14 and 21 days days until the end of the study of each cohort
|
1, 7, 14 and 21 days
|
ACE1, ACE2, TMPRSS2 and furin gene expression levels from baseline to 21 days placebo in each cohort
Time Frame: 1 and 21 days
|
ACE1, ACE2, TMPRSS2 and furin gene expression levels from baseline to 21 days
|
1 and 21 days
|
Presence of presence of ground-glass opacity, consolidations, parenchymal bands, and crazy-paving pattern in chest tomography from baseline to 7, 14 and 21 days
Time Frame: 1, 7, 14 and 21 days
|
Presence of presence of ground-glass opacity, consolidations, parenchymal bands, and crazy-paving pattern in chest tomography from baseline to 7, 14 and 21 days
|
1, 7, 14 and 21 days
|
Levels of inflammatory cytokines IL-6, IL-2, IL-7, IL-10,granulocyte-colony stimulating factor (GM-CSF), interferon-γ (IFN-γ) and Tumor Necrosis Factor (TNF-α) from baseline to 7, 14 and 21 days
Time Frame: 1,7,14 and 21 days
|
Levels of inflammatory cytokines IL-6, IL-2, IL-7, IL-10,granulocyte-colony stimulating factor (GM-CSF), interferon-γ (IFN-γ) and Tumor Necrosis Factor (TNF-α) from baseline to 7, 14 and 21 days
|
1,7,14 and 21 days
|
Levels of total white blood count (1000 per mm³) from baseline to 7, 14 and 21 days Days 1, 7, 14 and 21 days after the administration of supplement or placebo in each cohort
Time Frame: 1,7,14 and 21 days
|
Levels of total white blood count (1000 per mm³) from baseline to 7, 14 and 21 days
|
1,7,14 and 21 days
|
Levels of hemoglobin count (g/dl) from baseline to 7, 14 and 21 days Days 1, 7, 14 and 21 days after the administration of supplement or placebo in each cohort
Time Frame: 1,7,14 and 21 days
|
Levels of hemoglobin count (g/dl) from baseline to 7, 14 and 21 days
|
1,7,14 and 21 days
|
Total platelets count (1000 per mm³) from baseline to 7, 14 and 21 days Days 1, 7, 14 and 21 days after the administration of supplement or placebo in each cohort
Time Frame: 1,7,14 and 21 days
|
Total platelets count (1000 per mm³) from baseline to 7, 14 and 21 days
|
1,7,14 and 21 days
|
Levels of fibrinogen (g/L) from baseline to 7, 14 and 21 days Days 1, 7, 14 and 21 days after the administration of supplement or placebo in
Time Frame: 1,7,14 and 21 days
|
Levels of fibrinogen (g/L) from baseline to 7, 14 and 21 days
|
1,7,14 and 21 days
|
Levels of D-Dimer (µg/mL) from baseline to 7, 14 and 21 days
Time Frame: 1,7,14 and 21 days
|
Levels of D-Dimer (µg/mL) from baseline to 7, 14 and 21 days
|
1,7,14 and 21 days
|
Levels of Ferritin (µg/mL) from baseline to 7, 14 and 21 days Days 1, 7, 14 and 21 days after the administration of supplement or placebo in each cohort
Time Frame: 1,7,14 and 21 days
|
Levels of Ferritin (µg/mL) from baseline to 7, 14 and 21 days
|
1,7,14 and 21 days
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Roberto Badaró, Ph.D, SENAI CIMATEC
Publications and helpful links
General Publications
- Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, Zhao X, Huang B, Shi W, Lu R, Niu P, Zhan F, Ma X, Wang D, Xu W, Wu G, Gao GF, Tan W; China Novel Coronavirus Investigating and Research Team. A Novel Coronavirus from Patients with Pneumonia in China, 2019. N Engl J Med. 2020 Feb 20;382(8):727-733. doi: 10.1056/NEJMoa2001017. Epub 2020 Jan 24.
- Verity R, Okell LC, Dorigatti I, Winskill P, Whittaker C, Imai N, Cuomo-Dannenburg G, Thompson H, Walker PGT, Fu H, Dighe A, Griffin JT, Baguelin M, Bhatia S, Boonyasiri A, Cori A, Cucunuba Z, FitzJohn R, Gaythorpe K, Green W, Hamlet A, Hinsley W, Laydon D, Nedjati-Gilani G, Riley S, van Elsland S, Volz E, Wang H, Wang Y, Xi X, Donnelly CA, Ghani AC, Ferguson NM. Estimates of the severity of coronavirus disease 2019: a model-based analysis. Lancet Infect Dis. 2020 Jun;20(6):669-677. doi: 10.1016/S1473-3099(20)30243-7. Epub 2020 Mar 30. Erratum In: Lancet Infect Dis. 2020 Apr 15;: Lancet Infect Dis. 2020 May 4;:
- Hoffmann M, Kleine-Weber H, Schroeder S, Kruger N, Herrler T, Erichsen S, Schiergens TS, Herrler G, Wu NH, Nitsche A, Muller MA, Drosten C, Pohlmann S. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell. 2020 Apr 16;181(2):271-280.e8. doi: 10.1016/j.cell.2020.02.052. Epub 2020 Mar 5.
- FRITZ IB. Action of carnitine on long chain fatty acid oxidation by liver. Am J Physiol. 1959 Aug;197:297-304. doi: 10.1152/ajplegacy.1959.197.2.297. No abstract available.
- Brass EP. Pharmacokinetic considerations for the therapeutic use of carnitine in hemodialysis patients. Clin Ther. 1995 Mar-Apr;17(2):176-85; discussion 175. doi: 10.1016/0149-2918(95)80017-4.
- Kraemer WJ, Volek JS, Dunn-Lewis C. L-carnitine supplementation: influence upon physiological function. Curr Sports Med Rep. 2008 Jul-Aug;7(4):218-23. doi: 10.1249/JSR.0b013e318180735c.
- Ozturk MA, Kardas Z, Kardas F, Gunes T, Kurtoglu S. Effects of L-carnitine supplementation on respiratory distress syndrome development and prognosis in premature infants: A single blind randomized controlled trial. Exp Ther Med. 2016 Mar;11(3):1123-1127. doi: 10.3892/etm.2015.2964. Epub 2015 Dec 29.
- Hamming I, Timens W, Bulthuis ML, Lely AT, Navis G, van Goor H. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. J Pathol. 2004 Jun;203(2):631-7. doi: 10.1002/path.1570.
- Ciaglia E, Vecchione C, Puca AA. COVID-19 Infection and Circulating ACE2 Levels: Protective Role in Women and Children. Front Pediatr. 2020 Apr 23;8:206. doi: 10.3389/fped.2020.00206. eCollection 2020. No abstract available.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 01/2021
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on COVID-19 Virus Infection
-
AudibleHealth AI, Inc.Sunrise Research Institute; Analytical Solutions Group, Inc.; Kelley Medical... and other collaboratorsCompletedCoronavirus Disease 2019 | SARS-CoV-2 Infection | COVID-19 Pandemic | COVID-19 Virus Infection | Coronavirus Disease-19 | COVID-19 Virus Disease | 2019 Novel Coronavirus Disease | 2019 Novel Coronavirus Infection | 2019-nCoV DiseaseUnited States
-
Assistance Publique - Hôpitaux de ParisCompletedHeart Transplantation | COVID-19 Vaccine | COVID-19 Virus InfectionFrance
-
bioLytical LaboratoriesCompletedCOVID-19 | SARS-CoV-2 Infection | COVID-19 Pandemic | COVID-19 Virus Infection | Coronavirus Disease-19United States
-
KARE BiosciencesBiomedical Advanced Research and Development Authority; BioLink Life Sciences... and other collaboratorsRecruitingCOVID-19 Pneumonia | COVID-19 Respiratory InfectionIndia
-
Aga Khan UniversityCompletedCOVID-19 Respiratory Infection | COVID-19 Pandemic | COVID-19 Lower Respiratory InfectionPakistan
-
Catalysis SLCompletedRespiratory Tract Infections | Covid19 | SARS-CoV2 Infection | COVID-19 Pneumonia | COVID-19 Respiratory Infection | Viral Infection | Infection, CoronavirusKazakhstan
-
Mahidol UniversityClinixir Co., Ltd.; Program Management Unit-C (PMU-C), governed by Ministry...CompletedCOVID-19 Infection | COVID-19 VACCINEThailand
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingHematopoietic and Lymphoid Cell Neoplasm | Malignant Solid Neoplasm | BK Virus Infection | Symptomatic COVID-19 Infection Laboratory-Confirmed | Adenovirus Infection | Cytomegaloviral Infection | JC Virus InfectionUnited States
-
Leidos Life SciencesUnited States Department of DefenseActive, not recruitingCOVID-19 | Covid19 | Coronavirus Disease 2019 | SARS-CoV-2 Infection | SARS-CoV-2 Acute Respiratory Disease | COVID-19 Pandemic | COVID-19 Virus Infection | COVID-19 Virus Disease | 2019 Novel Coronavirus Disease | 2019 Novel Coronavirus Infection | 2019-nCoV Disease | 2019-nCoV InfectionUnited States
-
ProgenaBiomeRecruitingCoronaviridae Infections | COVID-19 | COVID 19 | COVID | Corona Virus Infection | Coronavirus | Gastrointestinal Microbiome | Gut Microbiome | Coronavirus-19 | Coronavirus 19United States
Clinical Trials on LCLT : 68% elemental L-carnitine and 32 % Tartric acid
-
China Medical University HospitalCompleted
-
Assiut UniversityCompleted
-
Shiraz University of Medical SciencesCompletedCombination Therapy of Hydroxyurea With L-Carnitine and Magnesium Chloride in Thalassemia Intermediaβ-Thalassemia IntermediaIran, Islamic Republic of
-
University of Erlangen-Nürnberg Medical SchoolUnknownCancer | Muscle Weakness | Weight Loss | Cancer Cachexia | Muscle LossGermany
-
Khyber Medical University PeshawarCompleted
-
Maastricht University Medical CenterTop Institute Food and NutritionCompletedSCFA MetabolismNetherlands
-
Haisco Pharmaceutical Group Co., Ltd.RecruitingDiabetic Peripheral Neuropathic PainChina
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingAcute Lymphoblastic Leukemia | HyperbilirubinemiaUnited States
-
Maastricht University Medical CenterTop Institute Food and NutritionCompleted
-
Attikon HospitalCompletedAtrial FibrillationGreece